Chair: Steven Julious, Medical Statistics Group, University of Sheffield
Speakers: James Matcham, Amgen and Michael O'Kelly, Senior Director, Quintiles
Making available information from studies sponsored by the pharmaceutical industry: some current practices
Authors: Michael O'Kelly, Steven A. Julious, Stephen Pyke, Simon Day, Sue Todd, Jorgen Seldrup and James Matcham
Pharmaceutical Statistics, Volume 10, Issue 1, pages 60–69 January/February 2011 Abstract | Paper+ | Slides
Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials
Authors: James Matcham, Steven Julious, Stephen Pyke, Michael O'Kelly, Susan Todd, Jorgen Seldrup and Simon Day
Pharmaceutical Statistics, Volume 10, Issue 1, pages 70–73 January/February 2011 Abstract | Paper+ | Slides
The potential for bias in reporting of industry-sponsored clinical trials
Authors: Stephen Pyke, Steven A. Julious, Simon Day, Michael O'Kelly, Susan Todd, James Matcham and Jorgen Seldrup
Pharmaceutical Statistics, Volume 10, Issue 1, pages 74–79 January/February 2011 Abstract | Paper+
+ Papers available to view from 6th December 2011 to 3rd January 2012.
For a flier advertising the event, please click here.
Joint PSI, EFSPI & ASA BIOP Webinar: Estimands
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.